Back to mobile site

Oppenheimer Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)

August 13, 2024 6:54 AM EDT Send to a Friend
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $28.00 price target on Adverum Biotechnologies (NASDAQ: ADVM).The analyst comments "ADVM ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login